Welsh, Carson, Anderson & Stowe (WCAS) has announced it is committing up to $250 million to a newly formed platform that will invest in non-therapeutic companies supporting cell and gene therapy.

The platform — named Kiniciti and based in New York — plans to invest in a cross section of cell and gene therapy opportunities across multiple geographies.

WCAS, based in New York, is a private equity firm focused exclusively on the healthcare and technology industries. Founded in 1979, the firm targets growth-oriented companies with an investment strategy that is deal-size agnostic.